Hernández-Méndez EA, Oropeza-Barrera I, Dávila-Castro JJ, Sánchez-Cedillo A, Navarro-Vargas L, Noriega-Salas L, Vilatobá-Chapa M, Gabilondo-Pliego B, Contreras-Saldívar A, Uribe-Uribe N, Morales-Buenrostro LE, Alberú-Gómez J

Language: Spanish
References: 39
Page:
PDF size: 199.57 Kb.

ABSTRACT

Introduction. Acute rejection has been identified as the main cause of renal graft dysfunction during the first year after transplantation; it is associated with chronic structural and functional damage, which causes loss of graft and decrease in patient survival. Material and methods. We performed a retrospective and descriptive research consisting in a review of the final reports of biopsies performed due to renal graft dysfunction during the postransplant period. Patients included were transplanted at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) from January 2007 to December 2011. Results. A total number of 223 patients underwent renal transplantation during the period considered for this study purpose, 222 biopsies were performed due to renal graft dysfunction in 118 patients (52.9%). 74.5% of patients developed graft dysfunction in the first year after transplantation. The main histopathological findings reported were immunologic events in both living donor (LDRTR) and deceased donor renal transplant recipients (DDRTR), borderline changes were the most common diagnosis. The median time to detect immune events as cause of dysfunction was shorter for DDRTR and they tend to occur in the first 4 months after transplantation. Conclusion. We observed an incidence of 11.8% for acute rejection in the first year after transplantation for LDRTR and 17.4% for DDRTR. Further studies are needed to determine the causes of immunological events and their implications in the evolution of renal graft and patient’s survival.

REFERENCES

1. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331: 365.

2. Schnuelle P, et al. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term followup. J Am Soc Nephrol 1998; 9: 2135.

3. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis awaiting transplantation, and recipients of a First cadaveric transplant. N Engl J Med 1999; 341: 1725.

4. Aparna P, Fadi H, Donald E. Management of the Kidney Transplant Recipient. Prim Care Clin Office Pract 2008; 35: 433.

5. Opelz G, Döhler B. Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85: 661.

6. U.S. Department of Health & Human Services. Disponible en: http://optn.transplant.hrsa.gov [Acceso: 14 de diciembre 2012).

7. Nair R, et al. Late acute kidney transplant rejection: clinicopathological correlates and response to corticosteroid therapy. Transplantation Proceedings 2009; 41: 4150.

8. Meier-Kriesche H, Ojo A, Hanson J. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 1098.

9. Pallardo LM, et al. Acute rejection and late renal transplant failure: Risk factors and prognosis. Nephrol Dial Transplant 2004; 19: 2937.

10. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.

11. Vereerstraeten P, et al. Absence of deleterious effect on longterm kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63: 1739.

12. Pascual M, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.

13. Ishikawa, Akira, et al. Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome. Transplantation 1999; 68(9): 1318-24.

14. Humar A, et al. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000; 69: 2357.

15. Serdar Y, et al. Clinical predictors of renal allograft histopathology: a comparative study of single-lesion histology versus a composite, quantitative scoring system. Transplantation 2007; 6: 771.

16. Racusen LC, et al. The Banff ‘97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.

17. Racusen LC, et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.

18. Racusen LC, et al. Banff 2003 Meeting Report: New Diagnostic Insights and Standards. Am J Transplant 2004; 4: 1562.

19. Solez K, et al. Banff ‘05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’). Am J Transplant 2007; 7: 518.

20. Solez K, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 4: 753.

21. Sis B, et al. Banff ‘09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.

22. Mengel M, et al. Banff 2011 meeting report: new Concepts in antibody-mediated rejection. Am J Transplant 2012; 3: 563.

23. Bates WD, et al. An evaluation of the Banff classification of early renal allograft biopsies and correlation with outcome. Nephrol dial Transplant 1999; 14: 2364.

24. Sellarés J, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplantation 2012; 12: 388.

25. Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 Data Report. Am J Transplantation 2012; 1.

26. Chapman JR. Do protocol transplant biopsias improve kidney transplant outcomes? Curr Opin Nephrol Hypertens 2012; 21(6): 580.

27. Rotman S, Collins AB, Colvin RB. C4d deposition in allografts: current concepts and interpretation. Transplantation Reviews 2005; 19: 65.

28. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103-9.

29. Hirsch HH, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488.

30. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirusassociated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277.

31. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019.

32. Schold JD, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22: 626.

33. Van Aalderen MC, Heutinck KM, Huisman C, ten Berge IJ. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med 2012; 70: 172.

34. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.

35. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.

36. He X. Early acute rejection does not affect chronic allograft nephropathy and death censored graft survival. Transplan Proc 2004; 36(10): 2993.

37. Sijpkens YW, et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003; 75(2): 2004.

38. Wu JY, et al. Completely reverted acute rejection episodes do not influence the lonmg-term renal allograft survival. Zhongua Yi Xue Za Zhi 2003; 83(2): 106.

39. Madden RL, et al. Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients. Transplant Int 2000; 13: 344.